Current vaccination strategies are unlikely to eliminate measles, according to a new study led by faculty at the University of Georgia. The paper, which published today in The Lancet Global Health, explores the feasibility of eliminating measles and rubella using predominant vaccination strategies in 93 countries with the highest disease burden.
The David Geffen School of Medicine at UCLA has been awarded a $13.6 million grant from the Centers for Disease Control and Prevention to continue to study the effectiveness of COVID-19 vaccines and the long-term impact of infection among U.S. health care workers. The new yearlong grant project follows the 2020–21 Preventing Emerging Infections Through Vaccine Effectiveness Testing study, or PREVENT I, which was among the first to demonstrate the real-world benefit of mRNA vaccines in preventing symptomatic infection following their authorization by the Food and Drug Administration.
A new study uses a data-intelligent model to highlight the need to boost vaccination campaign budgets for disadvantaged, vulnerable populations to reach the maximum health benefit for everyone.
Key steps that everyone involved in pre-K - 12th grade schools can take to reduce the risk that COVID-19 will disrupt yet another school year.
Covid-19 vaccine companies influence each other's stock prices as well as market volatility, a team of scientists has found.
Despite recent claims on social media, the UK government has not changed its position on pregnant or breastfeeding women getting the COVID booster. The NHS says the vaccine is both safe and strongly recommended for this group.
To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boosts immune responses. In a step toward achieving that goal, one potential vaccine component has led to strong protection in primates by eliciting an antibody that binds to part of the virus’s outer envelope, reports a team led by researchers at the Duke Human Vaccine Institute (DHVI).
In the first year of its availability, 84.2% of US adults received at least one dose of COVID-19 vaccine.
A published study of 1,899 pregnant women nationwide representing all 50 states reveals that during the Covid-19 pandemic if a pregnant woman had lower socioeconomic status and/or were African American, she was less likely to have the intention of taking a Covid-19 vaccine or actually receiving it.
The latest research and expert commentary on pain management.
Based on findings from a new study by a Johns Hopkins Medicine-led research team, an effective means of fighting SARS-CoV-2, the virus that causes COVID-19, may be possible that circumvents the problem of waning immunity often observed when current vaccines deal with emerging COVID variants.
Arizona State University rose three spots to No. 8 for U.S. utility patents issued to universities worldwide in 2021, continuing to help drive American technological evolution and success. This marks the second time that ASU ranked in the top 10 among universities worldwide and the fourth time that ASU ranked in the top 10 among U.S.-based universities in the annual ranking by the National Academy of Inventors and the Intellectual Property Owners Association.
Being vaccinated with at least two doses of Pfizer vaccines dramatically reduces most of the long-term symptoms individuals reported months after contracting COVID-19, a new study shows.
Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests.
Getting an annual flu shot may be associated with a lower risk of stroke, according to a study published in the September 7, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Analysis across 67 countries highlights how among those who believe in COVID-19 conspiracy theories, a strong sense of morality increases support for COVID-19 prevention behaviors.
A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association’s flagship journal Circulation.
Researchers analyzed how the expectation of a vaccine influences optimal lockdown measures during a pandemic.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right